Although the robust antidepressant effects of the N-methyl-d-aspartate receptor (NMDAR)
antagonist ketamine in patients with treatment-resistant depression are beyond doubt, the …

N-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine (PCP),
dizocilpine (MK-801) and ketamine have long been considered a model of schizophrenia …

BackgroundThere is growing interest in glutamatergic agents in depression, particularly
ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist. We aimed to …

Neurons in the primate dorsolateral prefrontal cortex (dlPFC) generate persistent firing in the
absence of sensory stimulation, the foundation of mental representation. Persistent firing …

After a pause of nearly 40 years in research into the effects of psychedelic drugs, recent
advances in our understanding of the neurobiology of psychedelics, such as lysergic acid …

Depression is a widespread psychological disorder that affects up to 20% of the world's
population. Traditional Chinese medicine (TCM), with its unique curative effect in depression …

Traditional antidepressants require many weeks to reveal their therapeutic effects. However,
the widely replicated observation that a single subanesthetic dose of the N-methyl-D …

Ketamine, a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor, displays
a fast antidepressant activity in treatment-resistant depression and in rodent models of …

The chronic mild (or unpredictable/variable) stress (CMS) model was developed as an
animal model of depression more than 20 years ago. The foundation of this model was that …

In mood disorders, there is growing evidence for glutamatergic abnormalities derived from
peripheral measures of glutamatergic metabolites in patients, postmortem studies on …